HeartBeam Secures $10 Million in Public Offering to Accelerate Cardiac Technology Commercialization

HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction was completed on April 16, 2026, with support from key stakeholders including ClearCardio(TM), company leadership and institutional investors. The funds will be allocated toward commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes.

The company's technology represents a significant advancement in cardiac monitoring, creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining cardiac health management.

HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The cleared indications for use of the HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment are detailed on the company's website at https://www.heartbeam.com/indications.

The successful public offering provides critical capital for HeartBeam to advance its mission of transforming the detection and monitoring of critical cardiac conditions. By enabling portable, cable-free ECG monitoring that can be conducted outside traditional medical facilities, the technology addresses significant gaps in current cardiac care delivery. The funding will support both immediate commercialization efforts and ongoing research and development, particularly in extended-wear monitoring and AI-enhanced cardiac analysis capabilities.

This financial milestone comes at a pivotal time for the medical technology sector, where remote patient monitoring and portable diagnostic tools are increasingly important. HeartBeam's approach to synthesizing 12-lead ECGs from 3D signal collection represents a novel solution to longstanding challenges in portable cardiac monitoring. The company's progress through regulatory clearance and now significant funding positions it to potentially impact how cardiac conditions are detected and managed in ambulatory settings.